<p>隨着亞洲市場在表現不一和經濟變動的背景下進行調整，投資者密切關注在美中貿易緊張局勢緩解和日本股市創紀錄高點的情況下尋找機會。在這種情況下，識別具有強大基本面的被低估股票可以提供資本增值的潛力，尤其是在區域經濟適應不斷變化的全球條件時。</p>
<h3>基於現金流的亞洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>西安國際醫療投資（SZSE:000516）</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>Visional（TSE:4194）</td>
<td>¥9984.00</td>
<td>¥19579.10</td>
<td>49%</td>
</tr>
<tr>
<td>新西蘭國王三文魚投資（NZSE:NZK）</td>
<td>NZ$0.195</td>
<td>NZ$0.39</td>
<td>49.5%</td>
</tr>
<tr>
<td>美圖（SEHK:1357）</td>
<td>HK$8.80</td>
<td>HK$17.19</td>
<td>48.8%</td>
</tr>
<tr>
<td>聯創電子科技有限公司（SZSE:002036）</td>
<td>CN¥10.08</td>
<td>CN¥19.99</td>
<td>49.6%</td>
</tr>
<tr>
<td>Insource（TSE:6200）</td>
<td>¥845.00</td>
<td>¥1665.99</td>
<td>49.3%</td>
</tr>
<tr>
<td>Ibiden 有限公司（TSE:4062）</td>
<td>¥13855.00</td>
<td>¥27366.14</td>
<td>49.4%</td>
</tr>
<tr>
<td>國泉食品（上海）（SEHK:2517）</td>
<td>HK$4.00</td>
<td>HK$7.97</td>
<td>49.8%</td>
</tr>
<tr>
<td>重慶白鴨衞生用品（SZSE:003006）</td>
<td>CN¥22.33</td>
<td>CN¥44.01</td>
<td>49.3%</td>
</tr>
<tr>
<td>阿里巴巴健康信息技術（SEHK:241）</td>
<td>HK$5.73</td>
<td>HK$11.23</td>
<td>49%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 279 只被低估亞洲股票的完整列表。</p>
<p>我們將查看我們篩選工具中的一些最佳選擇。</p>
<h2>鉅子生物（SEHK:2367）</h2>
<p><strong>概述：</strong> 鉅子生物控股有限公司是一家投資控股公司，設計、開發、製造和銷售以重組膠原蛋白為特色的皮膚治療產品，市場覆蓋中華人民共和國，市值為 408.7 億港元。</p>
<p><strong>運營：</strong> 公司的收入主要來自個人產品部門，產生了 61.1 億人民幣的收入。</p>
<p><strong>公允價值折扣估計：</strong> 41.8%</p>
<p>鉅子生物的交易價格低於其估計公允價值的 41.8%，當前價格為 38.16 港元，估計公允價值為 65.51 港元。最近的收益增長為 27.9%，預計年利潤增長為 17.1%，超過香港市場平均水平，儘管收入增長預測為 18.2%，但現金流潛力依然強勁。分析師一致認為，預計價格將上漲 83.4%，進一步增強了其相對於同行和行業標準的相對價值。</p>
<ul>
<li>我們的綜合增長報告表明，鉅子生物有望實現顯著的財務增長。</li>
<li>解鎖我們對鉅子生物股票分析的全面見解，查看這份財務健康報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6553fa54-fe12-48d3-ad44-4efb3ec7ce4a/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6553fa54-fe12-48d3-ad44-4efb3ec7ce4a/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:2367 截至 2025 年 11 月的折現現金流</p>
<h2>西安諾瓦星雲科技（SZSE:301589）</h2>
<p><strong>概述：</strong> 西安諾瓦星雲科技有限公司設計和開發 LED 顯示控制解決方案，市場覆蓋中國及國際，市值為 156.7 億人民幣。</p>
<p><strong>運營：</strong> 公司的收入主要來自視頻圖像顯示控制行業，總計 33.2 億人民幣。</p>
<p><strong>公允價值折扣估計：</strong> 43.1%</p>
<p>西安諾瓦星雲科技的交易價格低於其估計公允價值的 43.1%，當前價格為 173 元，估計公允價值為 304.2 元，顯示出其基於現金流的低估。儘管最近淨收入有所下降，但預計年收益將顯著增長 29.3%，超過中國市場的平均水平，表明未來現金流潛力強勁。然而，預計三年後的股本回報率相對較低，為 18%。</p>
<ul>
<li>我們編制的增長報告表明，西安諾瓦星雲科技的未來前景可能向好。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解西安諾瓦星雲科技的動態。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef33fac9-2042-487f-849d-74481c44134a/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef33fac9-2042-487f-849d-74481c44134a/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SZSE:301589 截至 2025 年 11 月的折現現金流</p>
<h2>WT 微電子（TWSE:3036）</h2>
<p><strong>概述：</strong> WT 微電子有限公司在美國、台灣、中國及其他國際市場開發和銷售電子及通信組件，市值為 1727.3 億新台幣。</p>
<p><strong>運營：</strong> 公司的收入部門包括在美國、台灣、中國及其他國際市場的電子和通信組件銷售。</p>
<p><strong>公允價值折扣估計：</strong> 43.8%</p>
<p>WT 微電子的交易價格為 154 新台幣，顯著低於其估計公允價值 274.12 新台幣，顯示出其基於現金流的低估。最近的收益報告顯示，2025 年第三季度的淨收入為 38.2 億新台幣，較去年增長了 28.1%。預計年收益將顯著增長 26.9%，超過台灣市場的平均增長率，儘管高債務水平和温和的股本回報率預測為 16.7%。</p>
<ul>
<li>我們最近的增長報告提供了 WT 微電子業務前景的良好預測。</li>
<li>深入瞭解 WT 微電子的具體情況，請查看我們的詳細財務健康報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3d299a68-3ac1-4aa0-9689-35787acddbd6/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3d299a68-3ac1-4aa0-9689-35787acddbd6/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>TWSE:3036 截至 2025 年 11 月的折現現金流</p>
<h2>關鍵要點</h2>
<ul>
<li>解鎖更多寶藏！我們的基於現金流的被低估亞洲股票篩選工具為您挖掘了 276 家公司供您探索。點擊這裏揭示我們精心策劃的 279 只基於現金流的被低估亞洲股票列表。</li>
<li>對這些企業有投資嗎？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>通過 Simply Wall St 提升您的投資組合，這是尋求全球市場覆蓋的投資者的終極應用。</li>
</ul>
<h2>對其他可能性感興趣嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場波動。</li>
<li>充實您的投資組合，選擇那些顯示出強勁增長潛力的公司，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章並不構成財務建議。它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

鉅子生物

諾瓦星雲

<p>隨着亞洲市場表現不一，投資者正在尋找被低估的股票以實現潛在的資本增值。關鍵推薦包括鉅子生物、陝西諾瓦星雲科技和 WT 微電子，這些公司的交易價格均顯著低於其估計的公允價值。這些公司展現出強勁的基本面和預期的盈利增長，表明其現金流潛力強大。文章強調了深入分析的重要性，並列出了 279 只在亞洲被低估的股票，鼓勵投資者在不斷變化的市場環境中探索機會</p>

<p>As the Asian markets navigate a landscape marked by mixed performances and economic shifts, investors are closely watching for opportunities amid easing U.S.-China trade tensions and Japan's record stock market highs. In this context, identifying undervalued stocks with strong fundamentals can offer potential for capital appreciation, especially as regional economies adapt to evolving global conditions.</p>
<div class="lb-trans"><p>隨着亞洲市場在表現不一和經濟變動的背景下進行調整，投資者密切關注在美中貿易緊張局勢緩解和日本股市創紀錄高點的情況下尋找機會。在這種情況下，識別具有強大基本面的被低估股票可以提供資本增值的潛力，尤其是在區域經濟適應不斷變化的全球條件時。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基於現金流的亞洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Xi'an International Medical Investment (SZSE:000516)</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>Visional (TSE:4194)</td>
<td>¥9984.00</td>
<td>¥19579.10</td>
<td>49%</td>
</tr>
<tr>
<td>New Zealand King Salmon Investments (NZSE:NZK)</td>
<td>NZ$0.195</td>
<td>NZ$0.39</td>
<td>49.5%</td>
</tr>
<tr>
<td>Meitu (SEHK:1357)</td>
<td>HK$8.80</td>
<td>HK$17.19</td>
<td>48.8%</td>
</tr>
<tr>
<td>LianChuang Electronic TechnologyLtd (SZSE:002036)</td>
<td>CN¥10.08</td>
<td>CN¥19.99</td>
<td>49.6%</td>
</tr>
<tr>
<td>Insource (TSE:6200)</td>
<td>¥845.00</td>
<td>¥1665.99</td>
<td>49.3%</td>
</tr>
<tr>
<td>IbidenLtd (TSE:4062)</td>
<td>¥13855.00</td>
<td>¥27366.14</td>
<td>49.4%</td>
</tr>
<tr>
<td>Guoquan Food (Shanghai) (SEHK:2517)</td>
<td>HK$4.00</td>
<td>HK$7.97</td>
<td>49.8%</td>
</tr>
<tr>
<td>Chongqing Baiya Sanitary Products (SZSE:003006)</td>
<td>CN¥22.33</td>
<td>CN¥44.01</td>
<td>49.3%</td>
</tr>
<tr>
<td>Alibaba Health Information Technology (SEHK:241)</td>
<td>HK$5.73</td>
<td>HK$11.23</td>
<td>49%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>西安國際醫療投資（SZSE:000516）</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>Visional（TSE:4194）</td>
<td>¥9984.00</td>
<td>¥19579.10</td>
<td>49%</td>
</tr>
<tr>
<td>新西蘭國王三文魚投資（NZSE:NZK）</td>
<td>NZ$0.195</td>
<td>NZ$0.39</td>
<td>49.5%</td>
</tr>
<tr>
<td>美圖（SEHK:1357）</td>
<td>HK$8.80</td>
<td>HK$17.19</td>
<td>48.8%</td>
</tr>
<tr>
<td>聯創電子科技有限公司（SZSE:002036）</td>
<td>CN¥10.08</td>
<td>CN¥19.99</td>
<td>49.6%</td>
</tr>
<tr>
<td>Insource（TSE:6200）</td>
<td>¥845.00</td>
<td>¥1665.99</td>
<td>49.3%</td>
</tr>
<tr>
<td>Ibiden 有限公司（TSE:4062）</td>
<td>¥13855.00</td>
<td>¥27366.14</td>
<td>49.4%</td>
</tr>
<tr>
<td>國泉食品（上海）（SEHK:2517）</td>
<td>HK$4.00</td>
<td>HK$7.97</td>
<td>49.8%</td>
</tr>
<tr>
<td>重慶白鴨衞生用品（SZSE:003006）</td>
<td>CN¥22.33</td>
<td>CN¥44.01</td>
<td>49.3%</td>
</tr>
<tr>
<td>阿里巴巴健康信息技術（SEHK:241）</td>
<td>HK$5.73</td>
<td>HK$11.23</td>
<td>49%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 279 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 279 只被低估亞洲股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我們將查看我們篩選工具中的一些最佳選擇。</p>
</div><h2>Giant Biogene Holding (SEHK:2367)</h2>
<div class="lb-trans"><h2>鉅子生物（SEHK:2367）</h2>
</div><p><strong>Overview:</strong> Giant Biogene Holding Co., Ltd. is an investment holding company that designs, develops, manufactures, and sells skin treatment products featuring recombinant collagen in the People's Republic of China, with a market cap of HK$40.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 鉅子生物控股有限公司是一家投資控股公司，設計、開發、製造和銷售以重組膠原蛋白為特色的皮膚治療產品，市場覆蓋中華人民共和國，市值為 408.7 億港元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its Personal Products segment, which generated CN¥6.11 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自個人產品部門，產生了 61.1 億人民幣的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 41.8%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 41.8%</p>
</div><p>Giant Biogene Holding appears undervalued, trading at 41.8% below its estimated fair value of HK$65.51, with a current price of HK$38.16. Recent earnings growth of 27.9% and projected annual profit growth of 17.1% outpace the Hong Kong market average, highlighting strong cash flow potential despite slower revenue growth forecasts at 18.2%. Analysts agree on an expected price rise by 83.4%, reinforcing its relative value compared to peers and industry standards.</p>
<div class="lb-trans"><p>鉅子生物的交易價格低於其估計公允價值的 41.8%，當前價格為 38.16 港元，估計公允價值為 65.51 港元。最近的收益增長為 27.9%，預計年利潤增長為 17.1%，超過香港市場平均水平，儘管收入增長預測為 18.2%，但現金流潛力依然強勁。分析師一致認為，預計價格將上漲 83.4%，進一步增強了其相對於同行和行業標準的相對價值。</p>
</div><ul>
<li>Our comprehensive growth report raises the possibility that Giant Biogene Holding is poised for substantial financial growth.</li>
<li>Unlock comprehensive insights into our analysis of Giant Biogene Holding stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的綜合增長報告表明，鉅子生物有望實現顯著的財務增長。</li>
<li>解鎖我們對鉅子生物股票分析的全面見解，查看這份財務健康報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6553fa54-fe12-48d3-ad44-4efb3ec7ce4a/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/6553fa54-fe12-48d3-ad44-4efb3ec7ce4a/chart/dcf?theme=light"/></p>
<p>SEHK:2367 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>SEHK:2367 截至 2025 年 11 月的折現現金流</p>
</div><h2>Xi'an NovaStar Tech (SZSE:301589)</h2>
<div class="lb-trans"><h2>西安諾瓦星雲科技（SZSE:301589）</h2>
</div><p><strong>Overview:</strong> Xi'an NovaStar Tech Co., Ltd. designs and develops LED display control solutions both in China and internationally, with a market cap of CN¥15.67 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 西安諾瓦星雲科技有限公司設計和開發 LED 顯示控制解決方案，市場覆蓋中國及國際，市值為 156.7 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from the Video Image Display Control Industry, totaling CN¥3.32 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自視頻圖像顯示控制行業，總計 33.2 億人民幣。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 43.1%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 43.1%</p>
</div><p>Xi'an NovaStar Tech is trading at 43.1% below its estimated fair value of CNY 304.2, with a current price of CNY 173, highlighting its undervaluation based on cash flows. Despite recent net income declines, earnings are forecast to grow significantly at 29.3% annually, outpacing the Chinese market average and indicating strong future cash flow potential. However, return on equity is expected to be relatively low at 18% in three years.</p>
<div class="lb-trans"><p>西安諾瓦星雲科技的交易價格低於其估計公允價值的 43.1%，當前價格為 173 元，估計公允價值為 304.2 元，顯示出其基於現金流的低估。儘管最近淨收入有所下降，但預計年收益將顯著增長 29.3%，超過中國市場的平均水平，表明未來現金流潛力強勁。然而，預計三年後的股本回報率相對較低，為 18%。</p>
</div><ul>
<li>The growth report we've compiled suggests that Xi'an NovaStar Tech's future prospects could be on the up.</li>
<li>Click here and access our complete balance sheet health report to understand the dynamics of Xi'an NovaStar Tech.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們編制的增長報告表明，西安諾瓦星雲科技的未來前景可能向好。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解西安諾瓦星雲科技的動態。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef33fac9-2042-487f-849d-74481c44134a/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/ef33fac9-2042-487f-849d-74481c44134a/chart/dcf?theme=light"/></p>
<p>SZSE:301589 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>SZSE:301589 截至 2025 年 11 月的折現現金流</p>
</div><h2>WT Microelectronics (TWSE:3036)</h2>
<div class="lb-trans"><h2>WT 微電子（TWSE:3036）</h2>
</div><p><strong>Overview:</strong> WT Microelectronics Co., Ltd. develops and sells electronic and communication components across the United States, Taiwan, China, and other international markets with a market cap of NT$172.73 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> WT 微電子有限公司在美國、台灣、中國及其他國際市場開發和銷售電子及通信組件，市值為 1727.3 億新台幣。</p>
</div><p><strong>Operations:</strong> The company's revenue segments include electronic and communication components sales in the United States, Taiwan, China, and other international markets.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入部門包括在美國、台灣、中國及其他國際市場的電子和通信組件銷售。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 43.8%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 43.8%</p>
</div><p>WT Microelectronics is trading at NT$154, significantly below its estimated fair value of NT$274.12, highlighting its undervaluation based on cash flows. Recent earnings reports show strong performance with net income for Q3 2025 at NT$3.82 billion, up from NT$2.84 billion the previous year. Earnings are projected to grow significantly by 26.9% annually, surpassing Taiwan's market average growth rate and indicating robust future cash flow potential despite high debt levels and modest return on equity forecasts of 16.7%.</p>
<div class="lb-trans"><p>WT 微電子的交易價格為 154 新台幣，顯著低於其估計公允價值 274.12 新台幣，顯示出其基於現金流的低估。最近的收益報告顯示，2025 年第三季度的淨收入為 38.2 億新台幣，較去年增長了 28.1%。預計年收益將顯著增長 26.9%，超過台灣市場的平均增長率，儘管高債務水平和温和的股本回報率預測為 16.7%。</p>
</div><ul>
<li>Insights from our recent growth report point to a promising forecast for WT Microelectronics' business outlook.</li>
<li>Dive into the specifics of WT Microelectronics here with our thorough financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們最近的增長報告提供了 WT 微電子業務前景的良好預測。</li>
<li>深入瞭解 WT 微電子的具體情況，請查看我們的詳細財務健康報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3d299a68-3ac1-4aa0-9689-35787acddbd6/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/3d299a68-3ac1-4aa0-9689-35787acddbd6/chart/dcf?theme=light"/></p>
<p>TWSE:3036 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>TWSE:3036 截至 2025 年 11 月的折現現金流</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Unlock more gems! Our Undervalued Asian Stocks Based On Cash Flows screener has unearthed 276 more companies for you to explore.Click here to unveil our expertly curated list of 279 Undervalued Asian Stocks Based On Cash Flows.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖更多寶藏！我們的基於現金流的被低估亞洲股票篩選工具為您挖掘了 276 家公司供您探索。點擊這裏揭示我們精心策劃的 279 只基於現金流的被低估亞洲股票列表。</li>
<li>對這些企業有投資嗎？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>通過 Simply Wall St 提升您的投資組合，這是尋求全球市場覆蓋的投資者的終極應用。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>對其他可能性感興趣嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場波動。</li>
<li>充實您的投資組合，選擇那些顯示出強勁增長潛力的公司，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章並不構成財務建議。它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

亞洲市場價值股的選擇以實現潛在的資本增值